Table 2 Immunological marker of adult patients with primary HLH
number | NK ≥15.11% normal | CD107a (ΔCD107a) > 10% normal | CD107a (ΔMFI) ≥2.8 normal | ΔPRF1 NK ≥ 81% CTL ≥ 2% normal | ΔGranzymeB NK ≥ 77% CTL ≥ 6% normal | ΔSAP NK (26–70) % CTL (43–87) % normal | XIAP NK (59–100) % CTL(61–100)% normal | classification |
|---|---|---|---|---|---|---|---|---|
P01 | 18.68% | – | – | – | – | – | – | FHL2 |
P02 | 11.37% | – | – | – | – | – | – | FHL2 |
P03 | 10.74% | – | – | NK 6.93% CTL6.66% | NK 75% CTL 40% | – | – | FHL2 |
P04 | 1.74% | – | – | – | – | – | – | FHL2 |
P05 | 15.69% | – | – | – | – | – | – | FHL2 |
P06 | 9.9% | – | – | NK0.31% CTL0.16% | – | – | – | FHL2 |
P07 | 10.6% | – | – | – | – | – | – | FHL2 |
P08 | 16.20% | 20.05% | 3.0% | NK 78% CTL 51% | NK 97% CTL 94% | NK62.1% CTL57.69% | NK66.03% CTL90.96% | FHL2 |
P09 | 11.29% | 13.75% | 3.0% | NK 33% CTL 1% | NK 99.87% CTL 99.77% | – | – | FHL2 |
P10 | 9.86% | 29.95% | 3.7% | NK95.88% CTL49.19% | NK 97.02% CTL 95.80% | NK 86.88% CTL82.66% | NK 87.94% CTL 74.91% | FHL2 |
P11 | 13.5% | 10.76% | 2.5% | – | – | – | – | FHL3 |
P12 | 12.27% | 5.52% | 1.5% | NK89.36% CTL70.07% | NK77.35% CTL77.04% | – | – | FHL3 |
P13 | 17.59% | 9.18% | 5.9% | NK 85.1% CTL57.32% | NK 71.52% CTL55.00% | NK 65.92% CTL 69.03% | NK 95.52% CTL 97.61% | FHL3 |
P14 | 11.14% | 1.36% | 0.86% | – | – | – | – | – |
P15 | 13.57% | – | – | – | – | – | – | XLP-1 |
P16 | 11.08% | – | – | – | – | – | – | XLP-1 |
P17 | 5.4% | 9.36% | 2.2% | NK 89.42% CTL4.26% | NK 89.48% CTL 5.92% | – | – | GS-2 |
P18 | 13.67% | – | – | – | – | – | – | CHS |